x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Business Of Biotech

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business

business management

All Episodes

58:06

Topical Ocular Biologics with Claris Bio's Clarke Atwell

Business Of Biotech ·

2024/07/01

We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if successful in the clinic, its Neurotrophic Keratitis candidate will vastly improve the patient experience. It will also prove unequivocally that there'...

en

64:02

C&G Regulatory Guidance with Lineage Therapeutics'...

Business Of Biotech ·

2024/06/24

We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting foot anywhere near a healthcare clinic. Lineage emerged stronger, signing a collaboration and license agreement with Roche and Genentech later that y...

en

64:08

True DEI Value in Biopharma with Arcellx's Rami...

Business Of Biotech ·

2024/06/17

We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to be in it for the long run. Asked about his company’s rapid rise since taking the helm in 2021, CEO Rami Elghandour cites a few critical and risky d...

en

55:46

Mission-Driven Dementia Funding with DDF's Jonathan Behr

Business Of Biotech ·

2024/06/10

We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, t...

en

64:06

ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller

Business Of Biotech ·

2024/06/03

We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire. In fact, it was our guest on this episode of the Business of B...

en

56:38

Accelerating ADCs with Mythic Therapeutics' Brian...

Business Of Biotech ·

2024/05/27

We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indiciative of a young man who didn't want to make decisions. In retrospect, i...

en

57:35

The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's...

Business Of Biotech ·

2024/05/20

We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission in mind -- to help early clinical-stage companies like KSQ Therapeutics prepare for and enter their clinical stage on the best possible footing, a...

en

40:13

A New Prescription For PBMs with Allan Shaw

Business Of Biotech ·

2024/05/13

We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab. He also explains why an election year, al...

en

59:10

New Apps For AI in mRNA With Anima Biotech's Yochi...

Business Of Biotech ·

2024/05/06

We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software ...

en

59:11

Circular RNA with Orna Therapeutics' Tom Barnes,...

Business Of Biotech ·

2024/04/29

en

61:30

Physician + Biotech Builder with Tome Biosciences'...

Business Of Biotech ·

2024/04/22

en

56:54

Commercial Readiness with ImmunityBio's Bobby Reddy,...

Business Of Biotech ·

2024/04/15

en

49:47

Precision Drug Delivery with Ampersand Biomedicines'...

Business Of Biotech ·

2024/04/08

en

40:16

Funding Alzheimer's Tx Dev with ADDF's Karen Harris

Business Of Biotech ·

2024/04/01

en

73:54

The AI Impact with Generate:Biomedicines' Mike Nally

Business Of Biotech ·

2024/03/25

en

47:52

Strategic Deals with CinRx's Gavin Samuels, M.D.

Business Of Biotech ·

2024/03/18

en

31:32

Serial Success With Triumvira's Rob Williamson

Business Of Biotech ·

2024/03/11

en

50:43

The Innovator's Dilemma with Lumen Bioscience's Brian...

Business Of Biotech ·

2024/03/04

en

40:38

Precision Radiopharmaceuticals with Ratio's Jack...

Business Of Biotech ·

2024/02/26

en

51:07

Managing Mergers With Sail Biomedicines' Guillaume...

Business Of Biotech ·

2024/02/19

en

289 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...